{
    "id": 20689,
    "fullName": "GCNT3 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "GCNT3 over exp indicates an over expression of the Gcnt3 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9245,
        "geneSymbol": "GCNT3",
        "terms": [
            "GCNT3",
            "C2/4GnT",
            "C24GNT",
            "C2GNT2",
            "C2GNTM",
            "GNTM"
        ]
    },
    "variant": "over exp",
    "createDate": "04/04/2016",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15425,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adrucil (fluorouracil) treatment of colorectal cancer cells, overexpressing, Gcnt3, resulted in decreased cell proliferation and a reversal of resistance (PMID: 29855486).",
            "molecularProfile": {
                "id": 21173,
                "profileName": "GCNT3 over exp"
            },
            "therapy": {
                "id": 1715,
                "therapyName": "Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13229,
                    "pubMedId": 29855486,
                    "title": "The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29855486"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5552,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of talniflumate and Iressa (gefitinib) decreased viability of pancreatic cancer cell lines with high GCNT3 expression in culture (PMID: 26880801).",
            "molecularProfile": {
                "id": 21173,
                "profileName": "GCNT3 over exp"
            },
            "therapy": {
                "id": 3892,
                "therapyName": "Gefitinib + Talniflumate",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5098,
                    "pubMedId": 26880801,
                    "title": "Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880801"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21173,
            "profileName": "GCNT3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}